However, three ADCs are now relevant in this space: Tisotumab Vedotin was approved in 2021 for recurrent or metastatic cervical cancer (based on FDA accelerated approval) (79); Mirvetuximab Soravtansine, targeting folate receptor-alpha, was granted approval in 2024 following the MIRASOL trial, which demonstrated progression-free and overall survival benefits in patients with platinum-resistant ovarian cancer (80, 81); and Trastuzumab Deruxtecan, a HER2-directed ADC with a tumor-agnostic indication that includes HER2-positive gynecologic cancers. Here, ERBB2 is linked to ovarian carcinoma.